Franklin Resources Inc. Grows Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Franklin Resources Inc. grew its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 35.1% in the third quarter, Holdings Channel.com reports. The firm owned 29,440 shares of the company’s stock after acquiring an additional 7,647 shares during the quarter. Franklin Resources Inc.’s holdings in Kymera Therapeutics were worth $1,356,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in KYMR. Jennison Associates LLC grew its holdings in Kymera Therapeutics by 85.8% in the 3rd quarter. Jennison Associates LLC now owns 797,681 shares of the company’s stock valued at $37,754,000 after buying an additional 368,394 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Kymera Therapeutics by 7.2% during the 3rd quarter. Wellington Management Group LLP now owns 4,618,359 shares of the company’s stock valued at $218,587,000 after acquiring an additional 308,954 shares during the last quarter. FMR LLC grew its holdings in shares of Kymera Therapeutics by 5.8% in the third quarter. FMR LLC now owns 5,109,141 shares of the company’s stock valued at $241,816,000 after purchasing an additional 282,301 shares during the period. Driehaus Capital Management LLC acquired a new stake in Kymera Therapeutics during the second quarter worth about $6,669,000. Finally, Renaissance Technologies LLC purchased a new position in Kymera Therapeutics during the second quarter worth about $4,271,000.

Kymera Therapeutics Price Performance

KYMR opened at $40.11 on Friday. The business has a fifty day moving average price of $45.44 and a 200 day moving average price of $43.41. Kymera Therapeutics, Inc. has a 12 month low of $22.35 and a 12 month high of $53.27. The stock has a market capitalization of $2.60 billion, a price-to-earnings ratio of -17.14 and a beta of 2.16.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.01. The business had revenue of $3.74 million during the quarter, compared to the consensus estimate of $10.34 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business’s revenue for the quarter was down 20.9% on a year-over-year basis. During the same period in the previous year, the company posted ($0.90) earnings per share. On average, research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on KYMR. Guggenheim increased their price target on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Leerink Partners reiterated an “outperform” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research report on Friday. Leerink Partnrs upgraded Kymera Therapeutics to a “strong-buy” rating in a research report on Monday, September 9th. BTIG Research started coverage on Kymera Therapeutics in a report on Tuesday, December 10th. They set a “buy” rating and a $60.00 price target for the company. Finally, Wells Fargo & Company raised Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $38.00 to $57.00 in a research report on Monday, December 2nd. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $53.88.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.